Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06490627

Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia (BTM)

Sponsor: National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

Conditions Fetal Hemoglobin Genetic Disease Thalassemia Major

Interventions Thalidomide

Updated 3 times since 2024 Last updated: May 26, 2025 Started: Apr 22, 2024 Primary completion: Apr 22, 2025 Completion: Apr 22, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Fetal Hemoglobin and Genetic Disease, this trial is actively recruiting participants. The trial is conducted by National Institute of Blood and Marrow Transplant (NIBMT), Pakistan and has accumulated 3 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Jun 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2

First recorded

Apr 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

Data source: National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Karachi, Pakistan